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Abstract
Background: The Programme for Improving Mental Health Care (PRIME) sought to implement mental health care
plans (MHCP) for four priority mental disorders (depression, alcohol use disorder, psychosis and epilepsy) into
routine primary care in five low- and middle-income country districts. The impact of the MHCPs on disability was
evaluated through establishment of priority disorder treatment cohorts. This paper describes the methodology of
these PRIME cohorts.
Methods: One cohort for each disorder was recruited across some or all five districts: Sodo (Ethiopia), Sehore (India)
, Chitwan (Nepal), Dr. Kenneth Kaunda (South Africa) and Kamuli (Uganda), comprising 17 treatment cohorts in total
(N = 2182). Participants were adults residing in the districts who were eligible to receive mental health treatment
according to primary health care staff, trained by PRIME facilitators as per the district MHCP. Patients who screened
positive for depression or AUD and who were not given a diagnosis by their clinicians (N = 709) were also recruited
into comparison cohorts in Ethiopia, India, Nepal and South Africa. Caregivers of patients with epilepsy or psychosis
were also recruited (N = 953), together with or on behalf of the person with a mental disorder, depending on the
district. The target sample size was 200 (depression and AUD), or 150 (psychosis and epilepsy) patients initiating
treatment in each recruiting district. Data collection activities were conducted by PRIME research teams. Participants
completed follow-up assessments after 3 months (AUD and depression) or 6 months (psychosis and epilepsy), and
after 12 months. Primary outcomes were impaired functioning, using the 12-item World Health Organization
Disability Assessment Schedule 2.0 (WHODAS), and symptom severity, assessed using the Patient Health
Questionnaire (depression), the Alcohol Use Disorder Identification Test (AUD), and number of seizures (epilepsy).
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Discussion: Cohort recruitment was a function of the clinical detection rate by primary health care staff, and did
not meet all planned targets. The cross-country methodology reflected the pragmatic nature of the PRIME cohorts:
while the heterogeneity in methods of recruitment was a consequence of differences in health systems and
MHCPs, the use of the WHODAS as primary outcome measure will allow for comparison of functioning recovery
across sites and disorders.
Keywords: Cohort; depression, Alcohol dependence, Psychosis, Epilepsy, Low-income populations, Primary healthcare
Background
A recent estimation of the global burden of disease indi-
cated that mental, neurological and substance use (MNS)
disorders are among the world’s leading causes of disabil-
ity, accounting for 11.7% of the disability-adjusted life
years (DALYs) globally [1]. Depressive disorders account
for over 40% of DALYs for MNS disorders, with another
10% due to alcohol use disorders and 7% from psychosis.
These estimates have increased by 15%, from 2005 to
2015, mostly due to ageing populations [1]. The paucity of
available treatment for affected individuals is a major con-
tributor to this burden. Different studies have estimated a
mental health treatment gap of between 50 and 85%, with
higher estimates found in low-income countries and for
severe mental disorders [2, 3]. Emerging evidence provides
support for the effectiveness and cost-effectiveness of
treatment provision for several MNS disorders in low-
and middle-income country (LMICs) settings [4–7]. This
has formed the basis for the WHO mental health Gap Ac-
tion Programme (mhGAP) guidelines on detection and
treatment of MNS disorders by primary care providers
[8]. Despite the availability of evidence-based treatment
guidelines, actual implementation is a major challenge
and there is a need to evaluate whether integrated care
can reduce the burden of disability for adults affected by
MNS disorders.
The aim of the Programme for Improving Mental
Health Care (PRIME) consortium was to implement and
evaluate district-level mental health care plans (MHCPs)
in five LMIC settings [9] for four priority mental disor-
ders: depression, alcohol use disorder (AUD), psychosis
and epilepsy. The MHCP were informed by rigorous for-
mative research and a participatory engagement with
stakeholders [10]. Typically, these programmes include
the identification of a MNS disorders and the provision
of evidence-based mental health care by general health
care providers at the primary care level, an approach
known as task-sharing [11].
The evaluation of the MHCPs was carried out at
the level of the district, community, facility and pa-
tient, using a range of methodologies based on a the-
ory of change framework [12]. The impact of the
MHCPs on clinical, functional and economic out-
comes at the patient level was assessed through
cohorts of adults identified with priority mental disor-
ders, treated through the MHCPs and followed-up
over time. The aim of the PRIME cohorts is to evalu-
ate the implementation of the MHCPs on patient-
level outcomes, and demonstrate whether task-shared,
evidence-based treatments can be implemented at
scale in LMIC settings to reduce the burden of dis-
ability for adults affected by MNS disorders.
A broad overview of the PRIME evaluation designs, in-
cluding the cohort studies, has been published previ-
ously [12]. The aim of this paper is to provide a more
detailed description of the cross-country methods and
the methodological variations in each country site.
Methods
Objectives
The primary objective of the PRIME cohort studies is to
assess the impact of the MHCPs on disability and symp-
tom severity of adults diagnosed with a priority MNS
disorder. Secondary objectives include 1) assessing
change in productivity, economic status, stigma and dis-
crimination (including for caregivers); 2) assessing health
equity (e.g. by comparing the processes and outcomes of
care by sex and socioeconomic status); and 3) identifying
predictors of treatment effects.
Study design
The cohort protocol was developed within an evaluation
framework based on the Medical Research Council (MRC)
framework for complex interventions [13], and using a The-
ory of Change approach [12]. This allowed cross-country
research questions and resulting methods to be developed
and implemented, while allowing for variation in local pri-
orities. Based on the priority disorders included in the dis-
tricts’ MHCPs, separate cohorts were recruited, one for
each priority mental disorder. Participants for the depres-
sion and psychosis cohorts were recruited across all dis-
tricts, while the epilepsy and AUD cohorts only comprised
participants from selected districts.
Study setting: mental health care plans
The PRIME cohort study took place in the following five
low- and middle-income districts: Sodo (Ethiopia),
Sehore (India), Chitwan (Nepal), Dr. Kenneth Kaunda
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(Dr KK) (South Africa), and Kamuli (Uganda). The
MHCPs were developed according to the local needs
and contexts of each district, and influenced by its geo-
graphical, social and cultural profile [14]. These have
been described in detail [15–19]. Briefly, In Ethiopia,
India, Nepal and Uganda, the four districts MHCPs
adapted the mhGAP Intervention Guidelines [20] for
local contextual needs and available resources. In South
Africa, the MHCP uses an integrated set of chronic care
guidelines called Adult Primary Care (APC, previously
PC101), that has been adopted by the South African
government and that incorporates mental health to initi-
ate collaborative care [21].
All MHCPs comprised intervention packages at the
community, health facility and health service organisa-
tion levels [15–19]. The community level packages typic-
ally included components relating to raising awareness,
reducing stigma and discrimination, detecting and refer-
ring probable cases, as well as ongoing care, adherence
support and rehabilitation. The facility-level packages in-
cluded training and supervision to improve providers’
awareness, detection and psychosocial and/or psycho-
tropic interventions for patients with a diagnosis of a
priority disorder, and referrals to community or more
specialised care. Finally, health service organisation level
packages included aspects such as ensuring reliable sup-
ply of psychotropic medication, mechanisms for moni-
toring, capacity building and resource mobilisation.
All MHCPs also included basic psycho-education for
all patients with a priority disorder diagnosis, across all
districts. A basic or advanced psychosocial intervention
was also offered to patients with depression and/or
AUD, sometimes concurrently with medication, depend-
ing on symptom severity. In Nepal, a randomised con-
trolled trial was embedded in the cohort study: half of
the patients with depression or AUD received a basic
psychosocial intervention from health workers, which
included emotional support and psycho-education; the
other half received an advanced evidence-based psycho-
social intervention from non-professional community
counsellors – a behavioural activation based intervention
(depression) [22] or motivational activation intervention
(AUD) [23].
Psychotropic medication was prescribed for patients
with epilepsy and psychosis, with ongoing care and ad-
herence support provided at community level in
Ethiopia, South Africa and Uganda. More advanced psy-
chosocial treatment, in the form of family counselling
was also provided to patients with psychosis and epi-
lepsy at community level by community counsellors in
Nepal. In South Africa, the MHCP also included the
provision of a rehabilitation group intervention to
patients with a diagnosis of psychosis whose condition
was stable.
Participant eligibility
Table 1 provides an overview of the inclusion criteria
and recruitment methods used across the districts and
cohorts. Eligible participants had to meet the district’s
MHCP criteria for treatment initiation, had to be above
the country’s age of majority, be residents in the district,
fluent in the local language and willing to provide in-
formed consent. Patients with acute psychotic symptoms
or who were not capable of providing consent were not
eligible in any of the districts. In Ethiopia, however, con-
sent from the guardian or caregiver was acceptable if the
patient did not express objection to taking part in the
study. Having been diagnosed with an MNS disorder
prior to PRIME did not preclude patients from being eli-
gible for enrolment in the psychosis and epilepsy treat-
ment cohorts. While patients already receiving
treatment for depression or AUD at the time of recruit-
ment were not eligible for enrolment in Nepal and South
Africa, they were eligible for enrolment in Ethiopia,
India or Uganda.
The caregivers of patients with epilepsy or psychosis
were also recruited either with or in lieu of the patient
(see Table 1). A caregiver, identified by the patient with a
disorder, was defined as the adult who was primarily re-
sponsible for meeting the daily needs of the patient. In
Ethiopia, South Africa and Uganda, when possible, both
the patient with psychosis and their caregiver were re-
cruited, whereas in India, either one or the other were
recruited depending on the patient’s ability to participate
and complete the interview, determined by the trained
data collectors. If the patient showed signs of being dis-
oriented, having distorted communication or being un-
able to respond to questions, the patient was deemed
unable to participate, and the caregiver was recruited
and interviewed instead. In Nepal, caregivers were re-
cruited and interviewed on behalf of patients diagnosed
with psychosis, regardless of the patients’ ability to
complete the interview. In Ethiopia and Uganda districts,
caregivers were also recruited, in addition to the patients
with epilepsy.
In certain districts, patients were recruited into de-
pression or AUD comparison cohorts if they screened
positive for depressive or AUD on a screening instru-
ment, but were not diagnosed with depression or AUD
by a PHC staff member, and therefore not eligible for
treatment initiation as per the MHCP. Inclusion criteria
were otherwise the same as for patients recruited into
the depression and AUD treatment cohorts. More details
on this procedure is described below.
Recruitment process
Participants were recruited from primary health care
clinics implementing the MHCPs in each district. Re-
cruitment was conducted in several stages, again
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Table 1 Recruitment and data collection method for the PRIME cohorts
Sodo district, Ethiopia Sehore district, India Chitwan districta,
Nepal
Dr Kenneth
Kaunda, SA
Kamuli district, Uganda
District population 143,507 (total) [70] 318,314 (total) [71] 579,984 [72] 695,933 [73] 490,255 (total) [74]
Number of clinics
involved in
recruitment
9 facilities (8 health
centres, 1 hospital)
3 community health
centres
10 clinics 4 clinics 13 facilities (12 health
centres, 1 hospital)
Recruitment period
Depression Feb 2015 – Dec 2015 Nov 2014 – July 2015 Aug 2014 – Sept
2015
Aug 2014 – July
2015
Jan 2015 - Sept 2015
AUD Aug 2015 – Nov 2015 Nov 2014 – Aug 2015 Aug 2014 – Sept
2015
– –
Psychosis Dec 2014 – Jul 2015 Nov 2014 – Aug 2015 Aug 2014 – Sept
2015
Aug 2014 – Sept
2014
Aug 2015 – Sept
2015
Jan 2015 - Sept 2015
Epilepsy Dec 2014 – March 2015 – Aug 2014 – Sept
2015
– Jan 2015 - Sept 2015
Step 1 of recruitment – Detection of individuals with priority mental disorder
Depression 1. Diagnosis by mhGAP-
trained nurse or health
officer at clinic (MHCP)
1. mhGAP master chart
checklist (MHCP) at
community or clinic
2. PHQ-9 & AUDIT by case
manager (MHCP), or else
researcher, at clinic
3. Consultation with
medical officer (MO) at
clinic (MHCP)
1. Community
informant
detection tool
(CIDT), at
community
(MHCP)
2. PHQ-9 & AUDIT
by researcher, at
clinic
3. Consultation
with PHC worker
or medical officer
(MO), at clinic
(MHCP)
1. Consultation
with PC101
trained nurse or
doctor, at clinic
(MHCP)
2. PHQ-9 & AUDIT
by researcher, at
clinic
1. Consultation with
mhGAP trained nurse or
medical clinical officer,
at clinic (MHCP)
AUD 1. Single-question alcohol
screening test by mhGAP-
trained nurse or health
officer at clinic (MHCP)
2. AUDIT by mhGAP-
trained nurse or health
officer at clinic (MHCP)
–
Psychosis 1. Identification of
probable cases by HEWS
and community key
informant at community
level (MHCP)
2. mhGAP master chart
checklist by mhGAP-
trained nurse or health
officer used to identify
psychosis or bipolar
disorder (MHCP)
3. Confirmatory clinician
interview (OPCRIT) by
psychiatric nurse (MHCP)
1. mhGAP master chart
checklist, at community
or clinic (MHCP)
2. Consultation with MO,
at clinic (MHCP)
1. Community
information
detection tool
(CIDT), at
community
(MHCP)
2. Consultation
with PHC worker
or MO, at clinic
(MHCP)
1.Identified from
patient registry
Epilepsy 1. Identification of
probable cases by HEWS
and community key
informant at community
level (MHCP)
2. mhGAP master chart
checklist by mhGAP-
trained nurse or health
officer (MHCP) used to
identify epilepsy
3. Diagnostic accuracy
checked by neurologist in
sub-sample of 25.
– –
Step 2 of recruitment – recruitment and group allocation
Depression
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Table 1 Recruitment and data collection method for the PRIME cohorts (Continued)
Sodo district, Ethiopia Sehore district, India Chitwan districta,
Nepal
Dr Kenneth
Kaunda, SA
Kamuli district, Uganda
Recruitment done by
PRIME researcher;
Group allocation:
• Diagnosis made by
nurse or health officer:
diagnosed cohort
• No diagnosis but screen
positive on PHQ-9:
comparison cohort
Recruitment done by
PRIME researcher;
Group allocation:
• Diagnosis made by MO:
diagnosed cohort
• No diagnosis but screen
positive on PHQ-9 or
AUDIT: depression or
AUD comparison
cohorts
Recruitment done
by PRIME
researcher;
Group allocation:
• Diagnosis made
by PHC worker:
diagnosed
cohort
• No diagnosis but
screen positive
on PHQ-9 or
AUDIT: depres-
sion or AUD
comparison
cohorts
Recruitment done
by PRIME
researcher;
Group allocation:
• Diagnosis made
by nurse or
doctor:
diagnosed
cohort
• No diagnosis but
screen positive
on PHQ-9:
comparison
cohort
Recruitment done by
PRIME researcher;
• Group allocation:
Diagnosis made by
nurse: diagnosed cohort
• No participants recruited
in the comparison
cohort
AUD Diagnosis and
recruitment done
by PRIME researcher;
• Screen positive on
AUDIT: diagnosed
cohort
• No participants recruited
in a comparison cohort
n/a n/a
Psychosis Diagnosis and
recruitment done by
psychiatric nurse;
Diagnosed patient
recruited, together with
caregiver
Recruitment done by
PRIME researcher;
Diagnosis made by MO:
diagnosed patient or
caregiver recruited
Recruitment done
by PRIME
researcher;
Diagnosis made
by trained PHC
worker or MO:
caregivers of
diagnosed
patients recruited
Recruitment done
by PRIME
researcher:
patient recruited;
where possible,
caregiver also
recruited
Recruitment done by
PRIME researcher;
Diagnosis made by
nurse: diagnosed patient
recruited, together with
caregiver
Epilepsy Diagnosis and
recruitment done by
nurse or health officer;
Diagnosed patient
recruited, together with
caregiver
n/a Diagnosis given
by PHC worker or
MO: diagnosed
patient recruited
n/a
Assessments
Location and
timing of baseline
assessment
All cohorts: Facility-based;
if participants too unwell
to leave their home,
completed at home
All cohorts: Initiated at
facility, finalised at home
All cohorts:
Initiated at facility,
finalised at home
All cohorts:
Facility-based
Depression: Facility or
home-based (depending
on participant availability).
Psychosis and epilepsy:
Facility-based for
participant, home-based
for caregiver, or vice
versa.
Location and
timing of midline
assessment
• Facility-based - if
participants too unwell
to leave their home,
completed at home
• Depression, psychosis
and epilepsy: 6 months
post-baseline
• AUD: 3 months post-
baseline
• Home-based
• Depression and AUD:
3 months post-baseline
• Psychosis: 6 month
post-baseline
• Home-based
• Depression and
AUD: 3 months
post-baseline
• Psychosis and
epilepsy:
6 month post-
baseline
• Facility/Home-
based
• Depression:
3 months post-
baseline
• Psychosis: no
midline
• Home-based
• Depression: 3 months
post-baseline
• Psychosis and epilepsy:
6 month post-baseline
Location and
timing of endline
assessment
• Facility-based - if
participants too unwell
to leave their home,
completed at home;
• 12 months post-baseline
Home-based; 12 months post-baseline • Facility/Home
based;
12 months post-
partum
Home-based; 12 months
post-baseline
aThe implementation area includes 10 of the 36 Village Development Committees in Chitwan District
PHC=Primary health care; PHQ-9 = Patient Health Questionnaire – 9 item; AUDIT = Alcohol Use Disorder Identification Test; OCPRIT = Operational Criteria Checklist for
Psychotic Illness and Affective Illness; BRPSE = The Brief Psychiatric Rating Scale expanded version
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depending on how the MHCP operated. A description of
how individuals were detected in each district and each
cohort is provided below, as well as how, when and by
whom they were recruited.
Community-based case detection
Three of the districts had community-based case detec-
tion included in their MHCP, with identification and re-
ferral of individuals with probable priority mental
disorder in the community, either by community mem-
bers or community health workers. In Ethiopia, this took
the form of recognition of possible cases by health ex-
tension workers and community key-informants, trained
in vignettes comprising typical presentations of psych-
osis and epilepsy. These vignettes had been used in a
previous study for case ascertainment in a neighbouring
district [24]. In Nepal, community members (Female
Community Health Volunteers and mother groups) used
a Community Informant Detection Tool (CIDT; [25]),
specifically developed for the purpose of proactive iden-
tification of individuals in the community and to en-
hance help-seeking behaviours. The tool also makes use
of vignettes and pictures to help lay individuals recog-
nise relevant symptoms. In India, the mhGAP master
chart checklist was used to detect probable cases in the
community, which is based on the mhGAP guidelines.
Detection was undertaken by mental health case man-
agers, who were appointed as an additional human re-
source to facilitate the identification of individuals with
priority mental disorders.
Facility-based recruitment for common mental disorders
(depression and AUD)
All participants recruited in the depression and AUD
treatment cohorts were diagnosed by a primary health
worker, and all were screened with the Patient Health
Questionnaire (PHQ-9; [26]) and/or the Alcohol Use
Disorder Identification Test (AUDIT; [27]), before or
after their consultation. In general, participants who re-
ceived either a diagnosis of depression or AUD were re-
cruited in the depression or AUD treatment cohorts.
Participants who did not receive a diagnosis but
screened positive on the PHQ-9 or AUDIT, were re-
cruited into comparison cohorts (Table 1).
Specifically, in Ethiopia and Nepal, patients attending
the primary care facilities were screened by PRIME re-
searchers, using the PHQ-9, to identify potential partici-
pants to enrol into the depression treatment cohort. The
screening was done before the patients’ consultation
with a trained PHC worker or medical officer (MO)1 in
Nepal, and after the consultation with a trained nurse or
health officer in Ethiopia. PRIME researchers then
followed-up patients (Nepal) or the PHC staff (Ethiopia)
after the consultation to determine whether a diagnosis
of depression was made. In Ethiopia, participants were
only recruited into the depression comparison cohorts
in the last two months of recruitment. Before that, only
patients who screened positive and were diagnosed by
the PHC staff were recruited into the depression treat-
ment cohort.
The same process of recruitment applied for the AUD
treatment cohort treatment and comparison cohorts in
Nepal, but this time using the AUDIT as a screening
tool. In Ethiopia, patients were only recruited into the
AUD treatment cohort using a stepped approach: the
nurse or health officer first used a single-question alco-
hol screening test [28] to identify patients at risk of
AUD. If at risk, the AUDIT was then administered by
the same health provider, and patients screening positive
were recruited into the AUD treatment cohort by the
PHC workers.
In South Africa, participants were recruited from the
chronic care units in four primary health care clinics.
Recruitment into the depression treatment cohort
followed the same logic and process as in Ethiopia and
Nepal. However, while patients were approached by the
PRIME researchers for consent and recruitment before
their consultation with the nurse or doctor, they were
only screened with the PHQ-9 after their consultation. If
patients were diagnosed with depression by a doctor, or
identified with depression by a nurse,2 they were allo-
cated to the depression treatment cohort, regardless of
the screening scores. If patients had not been diagnosed/
identified with depression but screened positive on the
PHQ-9, they were recruited into the depression com-
parison cohort. If a diagnosis of depression was made at
a subsequent facility visit, participants in the comparison
cohorts were re-enrolled in the treatment cohort, and
previous data deleted.
In India, recruitment was conducted after the consult-
ation with the MO, but screening could be performed in
one of two ways: 1) by the case managers at the clinic,
after patients were suspected of having depression or
AUD based on the mhGAP master chart checklist (at
community or at the clinic), and prior to their consult-
ation with the MO; or 2) by PRIME researchers, after the
consultation with the MO, when screening was not con-
ducted by the case managers (due to lack of time or be-
cause screened negative on the mhGAP master chart
checklist). Similarly to Nepal and South Africa, if partici-
pants were diagnosed with AUD or depression by the MO
in India, participants were allocated to the cohort treat-
ment group. If they were not given a diagnosis but
screened positive on the PHQ-9 or the AUDIT (regardless
of who conducted the screening), the participants were al-
located to the depression or AUDIT comparison cohorts,
respectively. However, while the PHC worker or MO in
Nepal were masked to the results of the screening scores,
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these were made available to the MO in India, to assist
with diagnosis. In India, as in Nepal, priority was given to
AUD in case of dual diagnosis or when participants
screened positive on the PHQ-9 and AUDIT.
Finally, in Uganda, eligible patients were approached
and enrolled by PRIME researchers on the day they
received a diagnosis by a trained nurse or medical
clinical officer, based on the mhGAP guidelines. No
participants were recruited into the comparison co-
horts, and the PHQ-9 was administered as part of the
baseline assessment, after enrolment into the depres-
sion treatment cohort.
Facility based recruitment for psychosis and epilepsy
All patients recruited in the psychosis and epilepsy treat-
ment cohorts, besides those recruited in South Africa
had to have been diagnosed with the disorder by a PHC
staff – an MO (India and Nepal), a psychiatric nurse
(Ethiopia) or by a nurse (Uganda). In some instances,
identification and recruitment was performed in a
stepped manner.
In Ethiopia, the mhGAP master chart checklist was
used to identify patients at risk of psychosis or bipolar
disorder, and a clinician interview was then conducted
by a psychiatric nurse to confirm the diagnosis, using
the Operational Criteria Checklist for Psychotic Illness
and Affective Illness (OPCRIT) [29]. The mhGAP mas-
ter chart was also used to identify patients with epilepsy,
however confirmation of diagnosis was conducted by a
neurologist for a sub-sample of 25 patients. Once diag-
nosis was confirmed, the recruitment of participants in
the psychosis and epilepsy treatment cohort was done
by a mhGAP-trained nurse or health officer.
In India and Nepal, a suspected diagnosis of psychosis,
either based on the mhGAP master chart checklist
(India) or based on diagnosis by the PHC worker (in
both districts), excluded patients from other cohorts, re-
gardless of their screening scores on the PHQ-9 and
AUDIT. The reason for this is that, in cases of comor-
bidity, priority for treatment (and cohort allocation) was
given to the severe mental disorder, over CMDs.
In Uganda, participants were recruited by PRIME re-
searchers into the psychosis and epilepsy treatment co-
horts only once they were diagnosed by a trained nurse,
based on the mhGAP guidelines.
Finally, in South Africa, participants with psychosis
were identified from the clinic mental health patient
register and approached to participate in the study. They
had already been diagnosed with psychosis at a district/
tertiary hospital, were considered stable, and had been
referred back to primary health care for ongoing symp-
tom management. Diagnosis was not re-confirmed be-
fore recruitment.
Outcome measures
Primary outcomes
The cross-country sections or instruments included in
the baseline and follow-up assessments for each cohort
are presented in Table 2. The primary cross-country
outcome for all cohorts was functioning, measured
using the 12-item WHO Disability Assessment Sched-
ule (WHODAS 2.0). Disorder-specific cross-country
primary outcomes comprised clinical severity measures:
number of seizures for epilepsy, the AUDIT score for
AUD, and the PHQ-9 score for depression. The avail-
ability of specialist trained assessors limited the use of a
psychosis-specific severity measures to the Brief Psychi-
atric Rating Scale – Expanded version (BPRS-E; [30]) in
Ethiopia and South Africa, and the Positive and Nega-
tive Syndrome Scale (PANSS) in Nepal. The PHQ-9
was also collected as a secondary outcome for the
AUD, psychosis and epilepsy treatment cohorts, given
the comorbidity between depression and AUD [31], and
between depression and severe mental disorders, in-
cluding psychosis and epilepsy [32, 33]. The instru-
ments used to measure the primary outcomes are
described below.
WHO disability assessment schedule
Disability was assessed using the WHODAS 2.0 (12 or
36 items) [34], an instrument developed by WHO and
which has been validated in a range of settings and cul-
tures [35], including India [36], South Africa [35] and
Ethiopia [37]. The WHODAS was also previously used
in studies conducted in Ethiopia [38], Nepal [39, 40] and
Uganda [41]. The ‘item-response-theory’ (IRT) based
scoring was used, and is suggested to facilitate compari-
sons across populations [34].
Patient Health Questionnaire (PHQ-9)
The PHQ-9 [26] is a widely used screening tool for de-
pression among LMICs [42], and has previously been
validated in primary health care patients in South Africa
[43] and in India [44]. It was also recently validated in
the Ethiopia [45], Uganda [46], Nepal [47] and South Af-
rica [48] as part of the PRIME study. A cut-off of 10 was
used by all districts to identify probable cases of depres-
sion, apart from Ethiopia, where a cut-off of 5 was found
to be more culturally appropriate [45].
The Alcohol use Disorder Identification Test (AUDIT)
The AUDIT is a 10-item screening tool to identify
alcohol misuse, developed by WHO [27]. The
AUDIT has been validated in a range of settings
[49]. It was shown to have good psychometric prop-
erties among HIV-positive individuals in outpatient
care in South Africa [50], and was a valid and reli-
able measure in identifying dependent and hazardous
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drinkers in Eastern Nepal [51] and in New Delhi
and Bangalore in India [52, 53]. Amharic and Lu-
ganda versions of the AUDIT have not yet been vali-
dated, but the AUDIT was found to have acceptable
internal consistency among HIV-positive individuals
in South West Ethiopia [54] and Southwestern
Uganda [55]. Per WHO guidelines, the units of alco-
hol consumption for each item were locally contex-
tualised. Different cut-offs were used to identify
individuals with probable AUD: 8 in Ethiopia and
India, and 9 in Nepal.
Brief psychiatric rating scale – extended version (BPRS-E)
The BPRS-E is a 24-item tool used to assess change
in psychiatric symptoms among individuals with se-
vere mental disorders, such as bipolar disorder and
schizophrenia [30]. It is used in both clinical and re-
search settings [56, 57]. Though used to assess sever-
ity of symptoms in the psychosis treatment cohort in
Ethiopia and in South Africa, the reliability of the
BPRS-E has not been assessed in these two countries.
However, it has previously been used in both coun-
tries [58, 59], and evidence has generally shown the
Table 2 Assessment schedule for the PRIME cohorts
Data collected by questionnaire Depression Alcohol use disorders Psychosis Epilepsy
Months of follow-upa 0 3/6 12 0 3 12 0 6 12 0 6 12
Demographics characteristics ✓ ✓ ✓ ✓
Clinical Measures
WHO Disability Assessment Schedule (WHODAS 2.0) [34] ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Patient Health Questionnaire (PHQ-9) [26] ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Alcohol Use Disorder Identification Test (AUDIT) [27] ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Short Inventory of Problems – Recent (SIP 2-R] [75, 76] ✓ ✓ ✓
Suicidality (Composite International Diagnostic Interview -
suicidality module) [77]
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Epilepsy severity (developed by PRIME) ✓ ✓ ✓
Brief Psychiatric Rating Scale (BPRS-E) [30] ✓ ✓ ✓
Positive and Negative Syndrome Scale (PANSS) [78] ✓ ✓ ✓
Health Service Use
Group/community interventions (developed by PRIME) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Mental health services received (developed by PRIME) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Health Service use and costs (adapted from the Client
Service Receipt Inventory)
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Medication adherence
Morisky Medication Adherence Scale (4-item) [79] ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Medication adherence (adapted from Care for People
with Schizophrenia in India)
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Social and economic measures
Economic activity (adapted from WHODAS 2.0, added
items by PRIME)
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Severe Adverse Events (developed by PRIME) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Oslo 3-item Social Support Scale [80] ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Caregiver work burden - WHO Family Interview
Schedule (Impact) [81]
✓ ✓ ✓ ✓ ✓ ✓
Caregiver economic activity (adapted from WHODAS
2.0, items added by PRME)
✓ ✓ ✓
Stigma and discrimination
Discrimination and Stigma Scale [82] ✓ ✓ ✓ ✓
Caregiver stigma & discrimination - WHO Family
Interview Schedule (Stigma) [81]
✓ ✓
Human rights abuse by caregiver (developed by PRIME) ✓ ✓ ✓ ✓ ✓ ✓
a6 months for depression in Ethiopia
Baron et al. BMC Psychiatry  (2018) 18:61 Page 8 of 14
instrument to have a similar structure across different
countries and settings [60].
Positive and Negative Syndrome Scale (PANSS)
Due to lack of clinical capacity to conduct the clinical-
rated BPRS-E, the 14-item PANSS [61] symptom check-
list was used in Nepal to assess positive and negative
symptom severity among participants recruited in the
psychosis treatment cohort. The 14 items have 5 re-
sponse options, ranging from ‘never’ to ‘continuously’.
The PANSS’s reliability has not previously been assessed
in Nepal, but has been used successfully in previous
research conducted in India [61].
Secondary outcomes
A range of secondary outcomes for the participants were
collected at all assessment points, comprising economic
and health care expenditure measures, as well as stigma
and discrimination measures. Secondary outcomes for
the caregivers recruited in the psychosis and epilepsy
treatment cohorts were also assessed, and these included
caregiver work burden and stigma (Table 2).
Most secondary measures were standardised and
already validated in similar settings. Some sections of
the assessments, however, were developed or modified
by the PRIME team to answer specific questions, such as
clinical history, human rights abuse, or mental health
treatment or community-based interventions received.
Several secondary outcomes were optional, and each
country also included country-specific sections; for this
reason, assessments varied slightly across districts.
Data collection
Recruitment and data collection were initiated between
6 and 12 months after the start of the MHCP implemen-
tation in each district, which included training staff, set-
ting up supervision and leadership processes, as well as
sensitisation activities. This allowed for the services to
run for at least several weeks before recruitment started.
The baseline assessment was conducted following en-
rolment into the different cohorts. In India and Nepal
districts, baseline assessments were initiated at the clinic
and finalised in the participants’ home. The time elapsed
between the enrolment of patients and the completion
of the baseline interview could not exceed 7 days, and
was completed on average 1 day after enrolment in
Nepal, and after 3 days in India. In all other districts, the
baseline assessment was conducted all at once, at the
clinic or at the participants’ homes, on the day of diag-
nosis or enrolment (for comparison cohorts).
Despite the different methods of recruitment into the
different cohorts across the districts, an attempt was
made to retain cross-country consistency in the data col-
lection methods. All participants in the cohorts were
followed-up twice after the baseline assessment: for the
AUD and depression treatment cohorts, the first follow-
up was conducted three months after recruitment (+/−
2 weeks), except in Ethiopia where the first follow-up
occurred at 6 months; for the psychosis and epilepsy
treatment cohorts, the midline assessment was con-
ducted 6 months after recruitment (+/− 2 weeks). A later
follow-up assessment time for these two priority condi-
tions was planned in anticipation of needing more time
for patients to respond to treatment. The final follow-up
was conducted 12 months after recruitment for all co-
horts (+/− 4 weeks). Follow-up assessments were gener-
ally conducted in a private space at the participants’
home, though follow-up assessments were conducted at
the clinic in Ethiopia and South Africa if more conveni-
ent for the participant.
An android mobile device application (Mobenzi;
https://www.mobenzi.com) was used by interviewers to
administer questionnaires for all districts, besides
Ethiopia, where data were collected with paper and pen-
cil and double entered in Epidata [62]. The use of
Mobenzi, which allowed item skips and real-time scor-
ing, meant that assessments were completed more
quickly, with reduced human error and limited missing
or unnecessary data. The baseline assessment took on
average 1 h to administer on a Mobenzi device. Follow-
up assessments, which excluded certain sections such as
demographics or clinical history, were shorter and lasted
approximately 30 min. In Ethiopia, where data was col-
lected manually, assessment generally took longer to ad-
minister: approximately 1 h for the depression and AUD
assessments, and approximately 2.5 and 2 h for the
psychosis and epilepsy assessments, respectively.
Participants who could not be reached within the win-
dow period after at least three contact attempts were
considered suspended until the next assessment, when
an attempt to contact them was made again. Participants
who actively refused to be assessed at follow-up were
withdrawn from the cohort study. The reason for sus-
pending participants from follow-up was recorded. This
did not, however, affect the care they were receiving as
part of the MHCP. Participants who, on the other hand,
refused or discontinued treatment remained in the co-
hort and were still followed-up for their assessments.
Statistical analyses
Power calculations
Sample sizes were calculated for each cohort, based on a
20% reduction in severity of symptoms at 12 months,
with 90% power, two-sided alpha of 0.05, and 0.5 intra-
class correlation. The initial sample size calculation was
based on a one-sample analysis, so a one sample t-test
power calculation was performed – this provided sample
sizes between 30 and 70 depending on the standard
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deviation and instrument used for assessing symptom
change, based on previous studies reporting pre-post
screening scores [63–68]. However, an attrition rate of
15–20% at the end of the study was expected. Also, a
bigger sample was required to be able to evaluate equity
of the treatment effects (e.g. by gender and by socioeco-
nomic status), to identify predictors of treatment effect,
and to detect rare adverse events. The target sample size
for cohorts in each district was therefore set at 200 for
depression and AUD, and 150 for psychosis and epilepsy.
The achieved sample sizes for each cohort are reported
in Table 3.
Primary and secondary analyses
The primary analyses of the PRIME cohort studies is to
estimate the changes in disability and symptom severity
over time among patients diagnosed with a priority men-
tal disorder who initiated mental health care as part of
the district MHCP. Secondary analyses include estimat-
ing change in productivity, economic status, stigma and
discrimination; equity of primary and secondary out-
comes; and identifying predictors of change in primary
and secondary outcomes. Given the diversity of methods
of recruitment used across districts, analyses will be
stratified by district.
For change in continuous outcomes (e.g. WHODAS,
PHQ-9, AUDIT), one-sample t-test and linear regres-
sion will be used when outcomes are normally distrib-
uted, to assess change from baseline to midline, and
from baseline to endline. For skewed continuous out-
comes, Poisson or negative binomial regression will be
used instead, or in the case of extremely skewed out-
comes, a non-parametric alternative, such as the Wil-
coxon sign ranked test. For change in binary outcomes
(e.g. suicidality), analyses will be conducted using logis-
tic regression. The primary and secondary outcome
analyses will be stratified by sex and then by socioeco-
nomic status (lowest wealth to highest wealth) to assess
equity of outcomes. Where there is evidence of hetero-
geneity, the stratum-specific effect estimates will be
presented. Additional equity analyses will be considered
by each district (e.g. by caste in Nepal, and by rural vs.
urban residence in Ethiopia).
As mentioned above, four districts also recruited a
depression and AUD comparison cohort. Two sample
t-tests and linear, Poisson or negative binomial regres-
sions will be used to estimate the difference-in-
differences of outcome means at each time point in
comparison to the baseline. Baseline imbalances in
sociodemographic and clinical measures between the
Table 3 PRIME cohort sample sizes and attrition over time, by disorder and by district
Depression AUD Psychosis Epilepsy
Treatment Comparison Treatment Comparison Patient Caregivera Patient Caregiver
Ethiopia
Enrolled 92 39 51 – 300 300 304 304
Attrition at midline 10 (10.9%) 0 (0%) 1 (2.0%) 53 (17.7%) 53 (17.7%) 149 (49.0%) 149 (49.0%)
Attrition at endline 13 (14.1%) 2 (5.1%) 4 (7.8%) – 55 (18.3%) 55 (18.3%) 50 (16.4%) 50 (16.4%)
India
Enrolled 281 158 218 147 22 21b – –
Attrition at midline 39 (13.9%) 15 (9.6%) 27 (12.3%) 19 (12.9%) 4 (19.0%) 0 (0%)
Attrition at endline 56 (19.9%) 19 (12.1%) 43 (19.6%) 29 (19.7%) 4 (19.0%) 1 (5.0%) – –
Nepal
Enrolled 137 72 175 57 – 95 42 –
Attrition at midline 27 (19.7%) 23 (31.9%) 40 (22.9%) 29 (50.9%) 8 (8.4%) 2 (4.8%)
Attrition at endline 26 (19.0%) 17 (23.6%) 33 (18.8%) 22 (39.3%) – 9 (9.5%) 4 (9.5%) –
South Africa
Enrolled 217 236 – – 47 12 – –
Attrition at midline 24 (11.1%) 27 (11.4%) 34 (72.3%) 8 (66.7%)
Attrition at endline 40 (18.4%) 41 (17.3%) – 5 (10.6%) 2 (11.1%) – –
Uganda
Enrolled 64 – – – 51 50 181 171
Attrition at midline 3 (4.7%) 4 (7.8%) 6 (12.0%) 8 (4.4%) 8 (4.7%)
Attrition at endline 7 (10.9%) – – – 8 (15.7%) 12 (24.0%) 19 (10.5%) 24 (14.0%)
aCaregivers recruited together with patient, unless otherwise stated
bEither patient or caregiver recruited
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treatment and comparison cohorts in each cohort will
be adjusted in the models, if feasible. Also, when pos-
sible, multiple imputation methods will be used to ad-
just estimates for loss to follow-up.
Potential factors associated with primary and second-
ary outcomes at each follow-up visit will be assessed
using linear (or Poisson or negative binomial) regression
and logistic regression, for continuous and binary out-
comes, respectively.
Ethical considerations
This study was approved by the University of Cape Town’s
Health Sciences Faculty Human Research Ethics commit-
tee (HREC REF: 412/2011), South Africa, and by the
WHO Research Ethics Review Committee, Switzerland.
Each district also received Ethical approval from their
relevant local Research Ethics Committees. Consent forms
were translated in local languages and completed by all
participants who agreed to participate, and/or by their
caregivers, where appropriate. However, patients did not
need to provide permission for caregivers to be recruited.
Refusing to take part in the cohort study or discontinuing
participation after enrolment did not prevent patients
from receiving clinical care as part of the MHCP.
Discussion
Practical and operational issues
The practical and operational issues that arose during
recruitment and data collection in the PRIME treatment
cohorts, and how these issues were dealt with, are out-
lined below.
Sample size and attrition
The final sample size and follow-up rates of each cohort
in each district are reported in Table 3. The recruitment
of participants into the cohorts took longer than expected,
and was a function of the low detection rate by primary
health care staff, as described in the MHCP [15–19].
Refresher training sessions and continuous supervision to
ensure PHC workers were still proactive with detection
were put in place. Despite these efforts, and due to time
constraints relating to other PRIME-related research
activities, recruitment had to be discontinued before some
of the cohorts could reach the optimal sample size.
Attrition rates were, for the most part, within the attri-
tion range expected, and accounted for by the increased
sample size (Table 2.). Among participants recruited in
the treatment cohorts, attrition generally ranged between
4 and 20% for the midline assessment, and between 10
and 20% at the endline assessment, across districts and co-
horts. Migration was the main reason for loss to follow-up
for all cohorts. Particularly high attrition rates for depres-
sion and AUD comparison cohorts were reported in
Nepal, where 76.4 and 60.7% completed the endline
assessment, respectively. The primary reasons for non-
completion in these groups were participants no longer
wanting to take part in the study (35 and 23%, respect-
ively), or moving away from the district (47 and 50%, re-
spectively). Given that these participants were not
receiving care under the MHCPs, it is understandable that
they were perhaps more difficult to retain in the study,
compared to participants in the treatment groups.
Fewer midline assessments were conducted for the
psychosis treatment cohort in South Africa, since the
start of the 12-session group rehabilitation intervention
was delayed. This delay meant that not all participants
had completed the intervention by the end of the mid-
line assessment window. When this was the case, the
midline assessment was skipped and only a 12-month
(endline) follow-up was conducted. Limited resources
also meant that only half of the participants in the epi-
lepsy treatment cohort could be followed-up for their
midline assessment in Ethiopia.
Comparison cohorts
It was not feasible or ethical, given the study was taking
place in routine settings, to create a ‘regular’ control
group where the MHCPs were not implemented. For
this reason, though not ideal, a comparison cohort of
non-diagnosed individuals who screened positive on the
PHQ-9 or the AUDIT were also recruited in Ethiopia,
India, Nepal and South Africa. These comparison partic-
ipants provide an approximation of the trajectory of out-
comes for the treatment cohort participants, had the
latter not received treatment. There may, however, be
systematic differences between treatment and compari-
son cohort participants which may limit our ability to
make conclusive estimates of the treatment effects, even
after these are controlled for statistically.
Many of the difficulties encountered in the recruitment
and data collection procedures for the PRIME cohorts
emerged from the tension between research processes and
the implementation of mental health services as part of
the MHCP in the districts. This is especially reflected in
the relatively small samples sizes recruited for some co-
horts, timing of assessments in relation to the completion
of the treatment prescribed, and the inability, ethically, to
recruit diagnosed but untreated patients into comparison
cohorts. However, a rigorous process was involved in
identifying measures to include in the assessment over
time, based on the Medical Research Council complex
intervention framework [13] and the Theory of Change
[69]. Meaningful indicators of change were identified, as
well as the relevant locally-validated tools and instruments
to assess these indicators. This meant we could assess a
wide range of outcomes (i.e. functional, clinical, social and
economic), thereby providing a holistic perspective of pa-
tient recovery. So, while the heterogeneity in methods of
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recruitment largely reflected the differences in health sys-
tems and MHCPs, the use of common standardised tools
should also allow for comparability across sites. Finally,
the process and outcome measures collected as part of the
cohort study will enable us to identify which elements of
the districts’ MHCPs were implemented properly, which
should be revised, and which are necessary for success
outcomes for individuals with MNS disorders.
Endnotes
1Medical officers are considered doctors in Nepal and
India – they are recent graduates of medical school.
2Nurses were trained to detect depression but could
not make a formal diagnosis. However, they had the au-
thority to refer patients for psychosocial counselling and
for recruitment into the depression treatment cohort.
When medication was necessary, patients had to be di-
agnosed and prescribed medication by a medical doctor.
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